Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450801 · ClinicalTrials.gov registry record · Phase 2
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00450801 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 22 participants.
The verdict
NCT00450801, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Etoposide
- DRUG Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-04 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450801
The ClinicalTrials.gov registry entry for NCT00450801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00450801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450801 about?
NCT00450801 is a clinical study titled "R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma". RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works...
What is the current status of trial NCT00450801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2004-04. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00450801?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Etoposide (DRUG), Cytarabine (DRUG).
Who is sponsoring clinical trial NCT00450801?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.